Login
Companies $AQST
$3.76 +$0.00 (0.04%) After hours
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc.

aquestive.com

What Do They Do?

Manufactures oral-film medicines for pharmaceutical licensees and develops epinephrine product candidates for people with severe allergic reactions.

How Do They Make Money?

Pharmaceutical licensees pay for made-to-order products after quality checks; the company also earns royalties on licensees’ sales, fees for contracted development work as tasks or milestones are completed, and license payments when rights transfer or over the license term. It sells its own products when they ship.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical licensees order made-to-order products directly and handle marketing and sales themselves; other pharmaceutical companies contract for development work and intellectual-property licenses.

Customers above 10% of revenue, FY2025
of revenue from two customers (73%, 17%)
FY2024: 74% from two customers

Do Revenues Turn Into Profits?

No. It lost $83.8M in FY2025.

Operating income, FY2025
−160% of revenue
▼ −131% (Loss) vs FY2024 (−$30.8M, −53%)
Net income, FY2025
−188% of revenue
▼ −90% (Loss) vs FY2024 (−$44.1M, −77%)
Free cash flow, FY2025
−119% of revenue
▼ −48% (Loss) vs FY2024 (−$35.9M, −62%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −41%
vs $12.8M in Q3 FY2025
Net income
▼ −7% (Loss)
vs −$15.4M in Q3 FY2025
  • Oct 13, 2026 Gives Eton exclusive U.S. commercialization rights to Libervant Eton will handle U.S. commercialization while Aquestive remains the exclusive manufacturer and supplier under a supply agreement.

Shrinking. Revenue fell 12% in 4 years, from $50.8M in FY2021 to $44.5M in FY2025, about 3% a year.

Epinephrine delivery The older report described an epinephrine prodrug in sublingual film form; the latest describes a topical gel candidate.

Who Do They Compete With?

Competes with Teva, Viatris, Amneal Pharmaceuticals, Kaleo, U.S. Worldmeds, and ARS Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support